Genetic Determinants of Cell-Type-Specific Responses to Cardiotoxic Chemotherapeutic Agents
Doxorubicin (DOX) and 5-fluorouracil (5-FU) are effective for treating a variety of cancers, yet many patients taking these drugs experience adverse cardiovascular events that are severe enough to pause treatment, often prolonging the course of chemotherapy and reducing its efficacy. Individual risk for drug-induced cardiotoxicity is likely mediated, at least in part, by genetic variants that…
We haven't written up this one. bioRxiv has the full story — the link below goes straight to it.
